

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen



Intyg Certificat

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

(71) Sökande Amersham Pharmacia Biotech AB, Uppsala SE
Applicant (s)

(21) Patentansökningsnummer 9804465-4
Patent application number

(86) Ingivningsdatum 1998-12-22
Date of filing

Stockholm, 2000-03-28

För Patent- och registreringsverket
For the Patent- and Registration Office

A. Södervall

Anita Södervall

Avgift
Fee 170:-

PCT/EP 99/10123

EPO-DG 1

EJU 12. 04. 2000
09/869023

REC'D 15 MAY 2000	
WIPO	PCT

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

**A METHOD FOR THE REMOVAL/PURIFICATION OF SERUM ALBUMINS AND
MEANS FOR USE IN THE METHOD**

Technical field

The present invention concerns a method for the
5 separation/removal of a mammalian serum albumin from a solution
containing a mixture of proteins in order to obtain a
solution/preparation that is substantially devoid of the serum
albumin. The invention also concerns novel immobilized ligands
that are able to bind to one or more serum albumins.

10

Technical background


For a long time there has been a large demand for purified
mammalian serum albumins, for instance serum albumin of human
or bovine origin (HSA and BSA, respectively). For HSA this has
15 mainly depended on its therapeutic use as a plasma volume
expander. Originally serum albumins were obtained from
sera/plasma of the appropriate species origin. For some years
the focus has been to produce serum albumins recombinantly, in
particular HSA. For bacterially produced recombinant forms, it
20 has become urgent to remove host cell contaminants because they
may be hazardous in vivo to mammals. It has become apparent
that preparing HSA in transgeneic animals should be beneficial,
for instance in transgeneic cows. This latter alternative,
however, has the drawback that HSA will be present in mixture
25 with the HSA analogue of the host animal (for instance with BSA
if HSA is produced in cows). This has created novel
purification problems, for instance the specific removal of BSA
from HSA.

Various forms of affinity binding including ion exchange
30 binding have earlier been applied to the purification of serum
albumins. For affinity binding the general goal has been to
find a chromatographic media (ligand attached to a
chromatographic base matrix) that provide sufficient
specificity in order to remove either predetermined
35 contaminants or the serum albumin desired as the end product

Regberg/Ellström version to be filed 1998-12-17 2
from complex mixtures. The term binding includes
chromatographic as well as batch-wise alternatives.

Illustrative examples of ligands previously used and having
selectivity for serum albumins are given by Theodore Peters in
5 All about Albumin - Biochemistry, Genetics and Medical
Applications, (Ed. Theodore Peters, Jr., Academic Press (1996)
pages 77-126. Among low molecular weight ligands there may be
mentioned certain dyes of rather complex structure, for
instance Cibacron Blue.

10 The methods concerned in the present invention generally
provide that a mixture of compounds, in particular proteins,
containing a serum albumin is contacted with a ligand that has
affinity for the serum albumin and that is attached to a base
matrix. The conditions are adjusted such that the serum albumin
15 becomes bound (adsorbed) to the ligand. The matrix-bound
affinity ligand may be represented by the formula I



where M is the matrix, X the affinity ligand (ligand structure)
and B a spacer group through which X is attached to the matrix.

20 M may contain several groups X linked through spacers that may
be equal or unequal to B.

The expression "a ligand that is attached to a matrix"
includes also ligands that are possible to attach to a matrix
after having bound a serum albumin.

25

Objectives of the invention

The first objective of the invention is to provide novel
affinity methods for the removal of a serum albumin from a
mixture of proteins in order to produce the serum albumin in
30 substantially pure form or a preparation essentially free of
the removed serum albumin.

A second objective is to provide an affinity method as
defined above which is selective for a serum albumin that exist
in mixture with one or more other serum albumins.


35 A third objective is to provide new affinity matrices
carrying albumin binding ligands having selectivities for serum
albumins.

The methods referred to are based on a matrix that carries an albumin binding ligand.

The invention

It has now been discovered that there are compounds that bind albumin to be found among certain five-membered heterocycles condensed with a benzene ring. The heterocycles concerned contain two or three heteroatoms selected from oxygen, nitrogen and sulphur. It has also been found that this type of albumin-binding compounds can be used as affinity ligands attached to matrices for the purification/removal of serum albumins from liquids. It has also been found that this ability to bind albumin may differ depending on the species origin of the serum albumin.

The inventive method thus has the characterizing feature that the ligand X defined above has been selected from the group of compounds defined in the preceding paragraph and linked to an affinity matrix M through a spacer B. In particular X complies with the structure according to formula II:



The free valence binds to the spacer B.

R₁, R₂ and R₃ and R₄ are selected from hydrogen, electron-withdrawing groups and lower alkyl groups (C₁₋₁₀) that possibly are substituted with electron withdrawing groups and/or hydrophilic groups. Particular important alkyl groups R at the priority date contain 1-3, preferably one, carbon atom. Particular important electron withdrawing groups are at the priority date: the halogens, such as F, Cl and Br, which also may enhance a hydrophilic character of the ligand. A wellknown hydrophilic group is hydroxy (HO-) that, like the halogens,

when present on an alkyl group will enhance the hydrophilic character of the latter. Particular interesting groups R not being hydrogen comprise C_{1-10} , such as C_{1-4} , alkyl groups substituted with 1-3 halogen atoms, preferably fluorine, on
 5 carbons at none, one or two atoms distance from the ring structure. One, two or three of R_{1-4} may be different from hydrogen, although it is believed that in the preferred ligands X one or two of R_{1-4} should not be hydrogen. Non-hydrogen groups R_{1-4} may be located in the 4-, 5-, 6- and/or 7-position with
 10 preference for positions 4 and/or 6.

Z and Y are heteroatoms selected from nitrogen, oxygen and sulphur, possibly carrying one or two organic groups or hydrogens in addition to the heterocyclic ring they are part of. Normal valence rules corresponding to stable compounds,
 15 i.e. nitrogen may carry one or two groups, sulphur one group and oxygen none. The organic groups may be selected according to the same principles as R_{1-4} , with preference for smaller alkyl groups and hydrogen. Among the heteroatoms present in the
 20 heterocyclic ring nitrogen atoms may be positively charged by binding to atoms or groups via four valencies and sulphur via three valencies.

In an embodiment containing the most preferred ligand structures X at the priority date, Z and Y are $NR'R''$ and NR''' , respectively, where each of R' , R'' and R''' are
 25 selected according to the same principle as R_{1-4} or a free electron pair, with the proviso that a selected R_{1-4} group should provide a saturated sp^3 -hybridised carbon atom binding directly to the heterocyclic ring. The preferred ligand structures of this embodiment comprise that at most one of R'
 30 and R'' is a free electron pair or a hydrogen. In this latter embodiment R''' is typically a free electron pair.


The general idea is that the useful types of ligands shall have a pronounced hydrophilicity in order to increase the desired selectivity for serum albumins and to minimize binding
 35 of too many other kinds of proteins via hydrophobic interactions. It is therefore believed that ligand structures

Regberg/Ellström version to be filed 1998-12-17 5.

that bind albumin will be found by selecting or screening water-soluble organic compounds that

- a) exhibit a benzene ring fused to a five-membered heterocycle containing two or three, preferably two, heteroatoms selected from nitrogen, oxygen and sulphur and
- b) have been attached to a matrix M via a spacer B replacing a group or atom at any of the positions 1, 2, 3, 4, 5, 6 and 7.

Particularly interesting compounds have two ring heteroatoms which are present in position 1 and 3, respectively, such as those compounds complying with the general structure as given in formula III. Attachment to a matrix is preferably at the 2-position of the ring system. The screening methodology may be of the same kind as given in the Experimental Part.



Z' and Y' are heteroatoms selected according to the same rules as for Z and Y. In case they comprise nitrogen as the heteroatom they may be $\text{NR}_s'\text{R}_s''$ and NR_s''' , respectively. The substituents R_s^{1-4} and R_s' , R_s'' and R_s''' and the groups/atoms Y' and Z' are selected such that the compound III is soluble in water at a pH-value in the interval 1-11, preferably 1-7 (25° C). By solubility in water is meant at least 0.01 mg/ml, with preference for at least 0.1 mg/ml. Typically this means that, when one or more of R_1-4 (for instance as defined for R_1-4 above) are alkyl groups with a relatively long carbon chain, there should also be present hydrophilic substituents, for instance hydroxy, amino, carboxy and other related substituents (ether, thioether, amido, ester etc), on the chain. The chain may also

be broken by one or more heteroatoms, such as sulphur (thioether), oxygen (ether) or nitrogen atoms (secondary, tertiary or quaternary amino). Preferably the compound (and the ligand structure) should exhibit a charge (positive or negative) in a part of this pH interval (positive in the lower part and/or negative in the upper part or positive all throughout the pH-interval 1-10. It is believed that screening for binding preferentially should take place at a pH where the ligand structure have a charge ≥ 0 , preferably > 0 . This includes that the charge may be located at a nitrogen in any of the groups R_{1-4}^s and R_s' , R_s'' and R_s''' or even in the spacer B.

At the priority the preferences with respect to R_{1-4}^s and R_s' , R_s'' and R_s''' were the same as for R_{1-4} , R' , R'' and R''' and Y and Z.

The hydrogen (H) in position 2 may be replaced by the part of the spacer B that is next to X in formula I, for instance a part containing a spacer chain of at most 10 atoms in length.

The matrix and the attachment of the ligand to the matrix.

In the preferred modes of the invention the ligand is attached to a base matrix that is insoluble in the aqueous media used. Such matrices often are based on polymers that expose a hydrophilic surface to the aqueous media used, i.e. expose hydroxy (-OH), carboxy (-COOH), carboxamido (-CONH₂, possibly in N- substituted forms), amino (-NH₂), oligo- or polyethylenoxy groups on their external and, if present, also on internal surfaces. Typically the matrices are of the same kind as those normally used as chromatographic matrices. The polymers may, for instance, be based on polysaccharides, such as dextran, starch, cellulose, pullulan, agarose etc, which if necessary have been crosslinked, for instance with bisepoxides, epihalohydrins, 1,2,3-trihalo substituted lower hydrocarbons, to provide a suitable porosity and rigidity. The matrices may also be based on synthetic polymers, such as polyvinyl alcohol, poly hydroxyalkyl acrylates, poly hydroxyalkyl methacrylates, poly acrylamides, polymethacrylamides etc. In case of

hydrophobic polymers, such as those based on divinyl and monovinyl substituted benzenes, the surfaces of the matrices are often hydrophilized to expose hydrophilic groups as defined above.

- 5 The matrices may also be of inorganic nature, e.g. silica, zirkonium oxide etc.

Physically the insoluble matrices may be in the form of porous monoliths or in beaded/particle form that can be either porous or non-porous. Matrices in beaded/particle form can be
10 used either as a packed bed or in suspended form. Suspended forms include so called classified expanded beds and pure suspensions in which the particles/beads are moving round completely. In case of monoliths, packed bed and classified expanded beds, the separation procedure may be classified as a
15 normal chromatography with a concentration gradient of adsorbed molecules being established along the flow direction. In case of pure suspension the separation procedure will be in the batch wise mode.

For suspensions, the beads/particles may contain a densifying
20 filler material that will permit higher flow rates in case of classified expanded beds and facilitate sedimentation of the beads/particles after adsorption. See for instance WO-A-9717132 (Amersham Pharmacia Biotech AB) and WO-A-9200799 (Upfront Chromatography).

- 25 The matrices may also comprise so called extenders carrying several groups -B-X. Extenders are often polymeric providing attachments of several ligands per spacer. Extenders are often hydrophilic and called tentacles etc. See for instance International Patent Application PCT/SE98/00189 (Amersham
30 Pharmacia Biotech AB).

A spacer is typically introduced to improve the availability of the ligand and/or facilitate the chemical coupling of the ligand to the matrix. Spacers often comprise a hydrocarbon chain that has a length between 1-50 atoms. The hydrocarbon
35 chain may be straight, branched or cyclic and optionally broken with one or more ether oxygen or amino nitrogen atoms and/or optionally substituted with one or more hydroxy, lower alkoxy,

or amino group ($-\text{NH}_2/\text{NH}_3^+$, where each hydrogen may be replaced with a lower alkyl or a lower acyl group). By lower alkyl or lower acyl group is primarily intended C_{1-10} alkyls/acyls. The spacer group may also, depending to coupling methodology, comprise ester, amido, thioether, etc groups that have the sufficient hydrolytic stability. This latter groups may be present in the spacer either alone or combined with each other and/or with the appropriate hydrocarbon chain(s).

In the spacer the atom binding directly to the ligand structure X should preferably be a sulphur atom, preferably bound to a saturated carbon atom in the spacer. In other alternatives of the spacer, the atom next to the ligand structure X may be an oxygen, a nitrogen (amino or amido nitrogen), a carbon (for instance a saturated carbon, carbonyl carbon etc). Typical saturated carbon atoms are only binding carbons and/or hydrogen.

The spacer, in particular the part closest to ligand structure X, may influence the ability to bind to serum albumin. The discussion above therefore primarily indicates the group of spacers that is to be screened for finding the optimal spacer for various ligand structures.

It can be envisaged that the ligand potentially also will be attached to the matrix by methods involving non-covalent bonding, such as physical adsorption or biospecific adsorption. In these cases the ligand may be covalently attached, via a spacer structure, to some type of carrier molecule that provides the ligand with sufficient adsorption ability relative adsorbing structures in the matrix. The carrier molecule and the adsorbing structures are in these cases regarded as being part of the matrix (M'). Pairs of carrier molecules and adsorbing structures may be represented by the biotin-streptavidin system.

As a potential alternative, the ligand may be in soluble form that subsequent to binding to a serum albumin is insolubilized. This may be accomplished, for instance, by having the ligand conjugated to biotin and insolubilizing by contacting the formed complex between the serum albumin and the soluble

ligand-biotin conjugate with a strepavidin-matrix. The spacer in this mode will be the grouping linking the ligand to biotin.

The sample containing the serum albumin to be removed/purified

5 The serum albumin to be removed and/or purified typically exists in mixture with other proteins and/or biomolecules. Illustrative examples are blood preparations (such as plasma and serum), fermentation liquids obtained from cultured host cells that have been transformed to express a serum albumin, 10 biological fluids obtained from transgeneic mammals transformed to produce a serum albumin of another species, and also various working up preparations derived from any one of these types of liquids. In case of liquids derived from transgeneic animals the liquids will often contain also the normal serum albumin of 15 the species concerned.

Procedural steps for binding

During the adsorption step the conditions are selected so as to promote binding between the ligand and the serum albumin 20 intended.

For pH this means that the pH-value shall be selected above the value at which serum albumin unfold. This value in turn may depend on ionic strength and temperature. The uppermost end of the pH is limited at the pH value at which hydrolytic 25 degradation becomes significant. As a general rule of thumb, the appropriate pH values will therefore be found in the range 4-10. However, our present findings suggest that the binding may require a positive charge on the ligand structure. The very broad range 4-10 may therefore only be applicable to ligand 30 structures, including the spacer B, carrying a pH-independent charge, for instance Z being a quaternary ammonium group. In case one or more of Z, Y, R_{s1-4}^s and R_s' , R_s'' and R_s''' or B comprise a nitrogen that can be protonated and deprotonated in water, the ligand structure X plus the spacer B may exhibit a 35 positive charge which is pH-dependent. The lower part of the pH interval 4-10 will then be applicable, for instance pH 4-7.

The ionic strength should be selected in the interval corresponding to 0-3 M NaCl. Ionic strengths at the upper part of this interval are likely to promote binding via hydrophobic interactions. This means that albumin binding will be promoted at higher ionic strengths, but simultaneously also proteins with pronounced hydrophobic regions will bind more efficiently thereby decreasing the selectivity for serum albumins. The optimal ionic strength will therefore, among others, depend on what is to be removed from what.

10 The temperature is typically selected in the interval 0-40°C with preference for 4-37°C.

The optimal values of pH, temperature and ionic strength will depend on the species origin of the serum albumin to be removed/purified, contaminants, the ligand structure attached to the matrix etc.

After adsorption of the serum albumin, it may be further worked up, for instance by first desorbing the serum albumin and subsequently subjecting it to further adsorption steps, for instance on a cation or an ion exchanger, an hydrophilic matrix exhibiting hydrophobic groups (HIC-media) etc. Suitably desorption conditions may include change of pH, ionic strength, temperature and/or addition of compounds interfering with binding. The latter type of compounds may be a compound mimicking the ligand structure X present on the matrix, for instance a compound according to formula III possibly also exhibiting a relevant part of the spacer B. The main rules should then of course be not to change the conditions so that the serum albumin becomes irreversibly denatured. The adsorption step according to the invention may be preceded by other adsorption steps, for instance based on ion exchange or immune ligands. Illustrative examples of steps that can be combined with the present inventive adsorption step have been given, for instance, in US 5440018; US 5521287 and EP 699687 (all in the name of Green Cross Corp).

Regberg/Ellström version to be filed 1998-12-17 11

The goal of the separation processes used is to obtain albumin preparations intended for use in vivo. This means that the preparation should contain < 0,01 %, such as < 0,001 % proteins that are heterologous to the species to which the preparation is to be administered. HSA preparations, for instance, that are to be used in humans shall contain < 0,01 %, such as < 0,001 % BSA. All percentages are w/w. This means that in order to reach a therapeutically acceptable purity the serum albumin preparations obtained directly from the adsorption step of the present invention often will need to be combined with further working up steps, either prior or subsequent to the inventive adsorption step.

The invention is further defined in the appended claims and will now be further described by experimental support regarding the most preferred fragment.

EXPERIMENTAL PART

The purpose of the study was to immobilize a number of selected heterocycles condensed to a benzene ring (benzo compounds) to an epoxy activated matrix (Sephacrose 4FF, Amersham Pharmacia Biotech AB, Uppsala, Sweden) and test them for binding to human serum albumins and IgG in PBS buffer at pH 7. In order to facilitate attachment to the matrix the compounds were selected to carry a thiol group (at the 2-position). The ligand structures were:

No	ligand structure X	Manufacturer of coupled compound	Subst. μmole/ ml gel	Vt ml
1	Benzimidazol-2-yl	Aldrich	15.1	1.2
2	5-methyl-benzimidazol-2-yl	Aldrich	14.4	1.2

Regberg/Ellström version to be filed 1998-12-17 12

3	Benzothiazol-2-yl	Aldrich	8.4	
4	Benzoxazol-2-yl	Aldrich	12.2	1.2
5	4-bromo-6-(trifluoromethyl)-benzimidazol-2-yl	Maybridge	15.1	1.2
6	6-ethoxy-benzothiazol-2-yl	Aldrich	9.6	1.1
7	5-nitro-benzimidazol-2-yl	Aldrich	15.1	1.2
8	6-nitro-benzothiazol-2-yl	TCI-GB	6.8	1.2
9	5-chloro-benzothiazol-2-yl	Aldrich	9.6	1.2
10	5-methoxy-benzimidazol-2-yl	Aldrich	14.7	1.1
11	4-chloro-6-(trifluoromethyl)-benzimidazol-2-yl	Maybridge	14.3	1.2
12	5-chloro-1-isopropyl-benzimidazol-2-yl	Maybridge	18.2	1.2
13	5,6-dichloro-benzimidazol-2-yl	Maybridge	15.1	1.2

Regberg/Ellström version to be filed 1998-12-17 13

14	5-chloro-6-fluoro-benzimidazol-2-yl	Maybridge	14.9	1.1
----	-------------------------------------	-----------	------	-----

Test proteins: Human Serum Albumin (HSA) (Sigma), Bovine Serum Albumin (BSA) (Sigma) and IgG human normal (Pharmacia AB = Pharmacia & Upjohn, Stockholm, Sweden).

5

Buffers used in binding experiments:

1. PBS pH 7
2. 20 mM citrate buffer. Dissolve 2.52 g citric acid monohydrate and 1.90 g citric acid monosodium salt in 1000 ml MilliQ water.
3. 2 M NaCl. Dissolve 116.88 g in 1000 ml MilliQ.
4. West. Add 6.8 g sodium acetate to 840 ml MilliQ water. Adjust pH with hydrochloric acid. Add 47.9 lactose, 0.44 g calcium chloride and 20 ml 2M NaCl. Add MilliQ water to 1000 ml.

15

Test solutions:

- HSA (2 mg/ml in PBS)
- HSA (2 mg/ml in West)
- BSA (2 mg/ml in West)
- IgG (1.5 mg/ml in PBS; dilute 1 ampoule (165 mg/ml) to 100 ml).

20

Synthesis of affinity media: 100 ml of drained gel (Sephacrose FF (Amersham Pharmacia Biotech AB, Uppsala) were washed on a glass filter with 400 ml of distilled water and transferred to a round bottomed glass flask together with 5.5 g of sodium hydroxide dissolved in 30 ml of distilled water. The mixture was kept at 35°C. 80 ml of 1,4-bis(epoxypropoxy)-butan were added under vigorous stirring. After modest stirring for two hours the gel was washed with 1.5 l of distilled water.

In each synthesis 1 mmole of the compound to be coupled

25

30

Regberg/Ellström version to be filed 1998-12-17 14

(compounds 1-15) was dissolved in 5 ml DMSO. The epoxy gel was washed with DMSO followed by addition of the ligand solution to 5.0 g of gel. 2 drops of 45% sodium hydroxide solution were added to each reaction flask (pH about 11). The reaction

5 vessels were incubated at 40° C for 60 hours. The gels were filtered on glass funnels and were washed with the following solvents: 1. DMSO; 2. DMSO/water (1:1); 3. water; 4. THF; 5. water; 6. ethanol; and 7. water. The substitution degree was determined by elemental analysis.

10 **Packing of columns:** The gel slurry was poured into the column and packed by sucking the solution out with a syringe attached to the column outlet. The adapter was mounted on the column and the gel was equilibrated with about 10 columns of PBS buffer.

Binding of HSA or human IgG in PBS pH 7 - elution with
15 **citrate pH 3:** The column was equilibrated with PBS pH 7 after which 2.000 ml HSA (2 mg/ml) or IgG (16.5 mg/ml) was applied. The column was eluted first with buffer of pH 7 and then with buffer of pH 3 (citrate; wash buffer).

Binding of HSA and BSA in West pH 4.6 - step wise elution
20 **with PBS pH 7 and citrate pH 3 :** The column was equilibrated in West buffer pH 4.6 and 2.000 ml HSA (2 mg/ml) or BSA (2 mg/ml) was applied. Elution was made West pH 4.6 then with PBS pH 7 and finally with citrate pH 3.0 (wash).

25 **RESULTS:**

Binding of HSA or human IgG in PBS pH 7 - elution with
citrate pH 3: Based on conventional ways of interpreting the chromatogram recorded, none of the ligand structures showed binding to IgG or HSA. The buffer was the standard for this
30 type of experiments with serum albumin (PBS pH 7). In spite of these negative results the present inventors went further on and analysed in more detail the shape and position of the peaks of the chromatograms. It was found that for HSA the chromatograms sometimes looked somewhat different for different
35 ligand structures. All chromatograms for IgG looked the same and the position of the eluted IgG suggested no

Regberg/Ellström version to be filed 1998-12-17 15

interaction/binding. For seven (3, 4, 6, 8, 9, 12 and 13) out of the 14 tested ligand structures the chromatograms looked the same with the HSA peak located at the same elution volume and having the same shape.


5 The HSA chromatograms from the other seven columns (1, 2, 5, 7, 10, 11 and 14) could be paired, two by two, due to a similarity and/or retardation of the peaks compared to the peaks for the previously discussed ligand structures. The ligand structures 1 and 2 showed two peaks in the flow through
10 and ligand structures 7 and 14 showed peaks with a shoulder. At least the latter result together with the retardation suggest an interaction with the media. Ligand structures 5 and 11 gave retarded peaks that were tailed. A very small elution peak and a small peak when reequilibrating the column could
15 also be seen. The tailing and retardation suggested some type of weak interaction with the ligand structure on the media. Ligand structure 10 gave a small peak when reequilibrating the column.

Binding of HSA or BSA in West pH 4.6 - step wise elution with
20 **PBS pH 7 and citrate pH 3:** The column with ligand structure 11 was studied with HSA and with BSA. The chromatograms indicated that all HSA applied and a part of the BSA applied were bound in West pH 4.6 (no HSA was eluted until PBS pH 7 was applied, one portion/peak of BSA eluted with West 4.6 and another with
25 PBS pH 7).

CLAIMS

1. A method for enriching/removing a serum albumin from a mixture of other compounds by contacting said mixture with a ligand (= X), said ligand
 - a) having affinity for and enabling binding of the serum albumin and
 - b) being attached via a spacer (= B) to a base matrix (= M') insoluble in the aqueous media used,
 the matrix with the attached ligand being represented by

$$M-B-X$$
 where M is the matrix, B the spacer and X the affinity ligand, with the provision that M may contain further groups X linked via a spacer,
 characterized in that said ligand X has been selected among serum albumin-binding structures complying with the formulae



- in which
- a) the free valence bind to the spacer B;
 - b) R_{1-4} are selected from hydrogen, electron-withdrawing groups, such as halogens and lower alkyl groups (C_{1-10}) that possibly are substituted with electron withdrawing groups, such as halogens;
 - c) Z and Y are selected among oxygen, sulphur or nitrogen, with the provision that the nitrogen may carry a positive charge.
2. The method according to claim 1, characterized in that contact between the mixture and the media M-B-X is done in an aqueous media having a pH at which the -B-X carries a positive charge.

3. The method according to anyone of claims 1-2, **characterized** in that at least one of R₁₋₄ exhibit an electron withdrawing group, preferably selected among halogens such as fluorine.
- 5 4. The method according to anyone of claims 1-3, **characterized** in that the spacer have a sulphur atom next to X.
- 10 5. The method according to any one of claims 1-4, **characterized** in that Z and Y are nitrogens, one of which binding to a hydrogen and the ligand structure being charged depending of pH.
- 15 6. The method of anyone of claims 1-5, **characterized** in that said mixture derives from a host in which said serum albumin is human serum albumin.
- 20 7. The method of anyone of claims 1-6, **characterized** in that said ligand is attached covalently to said matrix.
8. The method of anyone of claims 1-7, **characterized** in that after the adsorption step said serum albumin is eluted from said affinity adsorbent and if necessary further processed.
- 25 9. An affinity matrix as defined in any of claims 1-5 and 7.
- 30 10. A method for screening for ligands structures that, when attached to an affinity matrix, bind albumin, **characteriz d** that water-soluble compounds that exhibit a benzene ring fused to a 5-membered heterocycle containing two or three heteroatoms, preferably two, selected from nitrogen, oxygen and sulphur after having been attached to a matrix, preferably in the 2-position, are screened for binding to albumin.

PAY 98-1224

Regberg/Ellström version to be filed 1998-12-17 18

11. The method of claim 10, characterized in that screening is taking place in aqueous solutions at a pH at which the ligand structure including and spacer binding to the matrix is positively charged.

5


10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

A B S T R A C T O F D I S C L O S U R E

A method for enriching/removing a serum albumin from a mixture of other compounds by contacting said mixture with
M-B-X

5 where M is matrix, B the spacer and X the affinity ligand, with the provision that M may contain further groups X linked via a spacer.

The characterizing feature is that said ligand X has been selected among serum albumin-binding structures complying with
10 the formulae



in which

- a) the free valence bind to the spacer B;
- b) R₁₋₄ are selected from hydrogen, electron-withdrawing groups, such as halogens and lower alkyl groups (C₁₋₁₀) that
20 possibly are substituted with electron withdrawing groups, such as halogens;
- c) Z and Y are selected among oxygen, sulphur or nitrogen, with the provision that the nitrogen may carry a positive
25 charge.

An affinity matrix as defined in the preceding paragraph.

A method for screening for ligands structures that, when
30 attached to an affinity matrix, bind albumin. The method has the characterizing feature that water-soluble compounds that exhibit a benzene ring fused to a 5-membered heterocycle containing two or three heteroatoms, preferably two, selected from nitrogen, oxygen and sulphur after having been attached to
35 a matrix, preferably in the 2-position, are screened for binding to albumin.